---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005176"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:20:48.013074+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance

## Summary
- Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.
- Adjusted EBITDA $2.24M, up 95.8% YoY; plasma revenue +12.6%, pharma patient affordability revenue +266.8%.
- Added 8 net new plasma centers (477 total) and 8 net new patient affordability programs (61 total) in Q2.
- FY 2024 revenue guidance raised to $56.5-$58.5M; adjusted EBITDA guided $9.0-$10.0M (15-17% of revenue).
- Exited quarter with $31.29M unrestricted cash and zero debt.

## SEC filing metadata
- accession: 0001683168-24-005176
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/0001683168-24-005176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005176
- JSON: https://secwatch.observer/filing/0001683168-24-005176.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.